|
MechanismCYP3A5 inhibitors |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with University of Nevada, Las Vegas Foundation
0 Patents (Medical) associated with University of Nevada, Las Vegas Foundation
100 Deals associated with University of Nevada, Las Vegas Foundation
100 Translational Medicine associated with University of Nevada, Las Vegas Foundation